← Back to Search

AIH for Spinal Cord Injury

Phase < 1
Recruiting
Led By Martin Oudega, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and females Veterans between 18-85 years
Chronic cSCI (1 yr of injury)
Must not have
AIH Exclusion Criteria (in addition to the above listed exclusion criteria): resting heart rate > 120 bpm, resting systolic blood pressure >180 mmHg, resting diastolic blood pressure >100 mmHg, self-reported history of unstable angina or myocardial infarction within the previous month, resting SpO2 > or equal to 95%, cardiopulmonary complications such as COPD
Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1st week, 2nd week, 4th week, 8th week, and 12th week

Summary

This trial looks at a new way to help people with spinal cord injuries improve their arm and hand function.

Who is the study for?
This trial is for adults aged 18-85 with chronic cervical spinal cord injury (cSCI) at least a year old, who can perform certain hand grips and have some sensory function in specific areas. It's not for those with severe heart conditions, uncontrolled medical issues, major depression or psychosis, history of head injury or stroke, metal plates in the skull, seizure history, CNS-affecting drugs use, pregnancy or ongoing spinal complications.
What is being tested?
The study tests whether combining acute intermittent hypoxia (rAIH) with motor training enhances upper limb function recovery after cSCI. Using an adult rat model first to inform human trials later on. Participants will undergo rAIH and exercise training versus sham treatments to compare effects on motor skills.
What are the potential side effects?
Potential side effects may include discomfort from hypoxia exposure such as shortness of breath or lightheadedness during sessions; exercise-related muscle soreness; and risks associated with D-cycloserine if used in humans could involve allergic reactions or neurological changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a veteran aged between 18 and 85.
Select...
I have had a spinal cord injury for over a year.
Select...
I can firmly grasp and hold objects.
Select...
I can pick up small objects and pinch them between my thumb and index finger.
Select...
My spinal injury is at the neck level or higher.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am taking medication that affects my brain and could make seizures more likely.
Select...
I have had a head injury or stroke in the past.
Select...
I do not have unmanaged lung, heart, or bone problems.
Select...
I have a history of seizures.
Select...
I had a condition before my spinal cord injury that made it hard for me to exercise.
Select...
I have a spinal condition like stenosis, spina bifida, or a herniated disk.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1st week, 2nd week, 4th week, 8th week, and 12th week
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1st week, 2nd week, 4th week, 8th week, and 12th week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in grip strength
Change in motor evoked potential size
Change in pinch strength

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: hypoxia plus training plus NMDA agonistExperimental Treatment3 Interventions
combined hypoxia treatment with exercise training and with NMDA agonist treatment
Group II: hypoxia plus trainingExperimental Treatment2 Interventions
combined hypoxia treatment with exercise training
Group III: sham hypoxia plus trainingPlacebo Group2 Interventions
combined sham hypoxia treatment with exercise training
Group IV: hypoxia plus training plus sham NMDA agonistPlacebo Group3 Interventions
combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
hypoxia
2013
N/A
~130
D-cycloserine
2013
Completed Phase 4
~1060
exercise training
2012
Completed Phase 4
~1230

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,666 Previous Clinical Trials
3,765,719 Total Patients Enrolled
Martin Oudega, PhDPrincipal InvestigatorEdward Hines Jr. VA Hospital, Hines, IL
1 Previous Clinical Trials
62 Total Patients Enrolled

Media Library

D-cycloserine Clinical Trial Eligibility Overview. Trial Name: NCT03780829 — Phase < 1
Spinal Cord Injury Research Study Groups: hypoxia plus training, hypoxia plus training plus NMDA agonist, sham hypoxia plus training, hypoxia plus training plus sham NMDA agonist
Spinal Cord Injury Clinical Trial 2023: D-cycloserine Highlights & Side Effects. Trial Name: NCT03780829 — Phase < 1
D-cycloserine 2023 Treatment Timeline for Medical Study. Trial Name: NCT03780829 — Phase < 1
~2 spots leftby Feb 2025